DLC-1 is a GTPase-activating protein that targets Rho (Kim et al., 2007), and as a tumor suppressor, DLC-1 is not only involved in hepatocarcinogenesis, but also inhibits the cancer progression and oncogenic autophagy of hepatocellular carcinoma (Wu et al., 2018) (Zhou et al., 2004). Here, RHO is linked to cancer.